A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Metformin (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 24 Aug 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016, as reported by ClinicalTrials.gov.